Nippon India Pharma Fund has been one of the top-performing schemes of the Nippon India Mutual Fund, especially over the last 15-20 years. Nippon India Pharma Fund’s regular plan is the chart-topper — both in SIP and lump sum performance — when compared with other Nippon India equity funds over 20 years. The fund has delivered 18.26% annualised returns through SIPs and 19.04% annualised returns through lump sum investments over the last 20 years.
Overall, the fund’s regular plan has been around for more than 21 years, having launched on June 5, 2004. Since inception, it has delivered an impressive 20.12% CAGR. In this story, we look at how much wealth an investor would have created through SIP and lump sum investments if they had started at inception.
SIP investment example (started 21 years ago at inception)
Monthly SIP: Rs 10,000
Annualised return (CAGR) in 21 year: 18.61%
Total amount invested: Rs 25,20,000
Total corpus after 21 years: Rs 2.48 crore
Lump sum investment example (started 21 years ago at inception)
One-time investment: Rs 1,00,000
Annualised return (CAGR) in 21 years: 20.12%
Total corpus after 21 years: Rs 51.34 lakh
(Data: Value Research)
Nippon India Pharma Fund details
Total assets: Rs 8,346.49 crore (as of 31 October 2025)
Expense ratio: 1.80% (as of 31 October 2025)
Standard deviation: 15.24
Beta: 0.89
Sharpe ratio: 0.95
Portfolio turnover: 0.41
NAV: Rs 515.3218 (as of 21 November 2025)
Nippon India Pharma Fund investment strategy
Nippon India Pharma Fund invests in a mix of large and mid-sized companies to give consistent returns. Its investments cover all major areas of the pharma and healthcare industry – domestic and international markets, branded and generic drugs, contract research and manufacturing services (CRAMS), and healthcare services like hospitals, insurance, and diagnostics.
The fund focuses on sectors that need less capital and are less affected by market ups and downs, but still have good growth potential and healthy cash flow. Increasing awareness about healthcare, rising demand from India’s population, and new growth areas like healthcare services, outsourcing, and specialty pharma are key drivers for this fund.
Fund’s portfolio: Top stocks
Sun Pharmaceutical: 12.67%
Divi’s Laboratories: 8.07%
Lupin: 7.26%
Cipla: 6.29%
Apollo Hospitals Enterprise: 5.97%
Dr. Reddy’s Lab: 5.62%
Vijaya Diagnostic: 3.42%
MedPlus Health Services: 3.32%
Gland Pharma Limited: 3.05%
GlaxoSmithKline Pharmaceuticals: 2.87%
Fund’s portfolio: Top sectors
Pharma & Biotech: 75.07%
Healthcare services: 21.28%
Retail: 3.32%
Miscellaneous: 0.41%
(Note: Past performance of a fund may or may not continue in the future. Investors should consult their financial advisor before making any investment decisions. Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully.)